Department of Dermatology and STD, Government Medical College, Srinagar, Jammu & Kashmir, India.
Photodermatol Photoimmunol Photomed. 2010 Oct;26(5):230-4. doi: 10.1111/j.1600-0781.2010.00540.x.
Narrowband ultraviolet B (NB-UVB) therapy has emerged as one of the most favored treatment options in patients with generalized vitiligo. The aim of combining topical agents is to improve the efficacy of NB-UVB in causing repigmentation in vitiligo.
The present study aims to study the effect of combining topical tacrolimus to NB-UVB therapy in causing repigmentation in vitiligo lesions.
This prospective single-blind study was performed on 80 patients of generalized vitiligo above 12 years of age who had symmetrically distributed vitiligo lesions on the face, trunk or limbs. The patients applied topical tacrolimus 0.1% ointment twice daily on selected symmetrically distributed lesions on the left side of the body. No topical agent was applied on the corresponding lesions on the right side. The patients also received whole-body NB-UVB exposure three times every week on non-consecutive days according to a set protocol. Lesions selected for the comparison analysis were photographed serially and assessed by a single-blinded observer for the extent or repigmentation achieved. The extent of repigmentation achieved was calculated on the basis of VASI scoring. The time taken for the initial repigmentation to start, the overall repigmentation achieved as well as any adverse effects were noted down and compared between the selected lesions on the two sides.
Seventy-four patients with 234 symmetrical vitiligo lesions were available for comparison analysis at the end of study period. The mean repigmentation achieved on the left-sided study lesions was approximately 71% (VASI score of approximately 4.0) as compared with 60.5% on the symmetrically distributed right-sided lesions (VASI score of 3.4). Moreover, the repigmentation started earlier on the study lesions on left side than on the right-sided ones. No significant adverse events were reported with the combination treatment.
Addition of topical tacrolimus increases the extent of overall repigmentation achieved with NB-UVB therapy in vitiligo and also reduces the cumulative NB-UVB dose needed to achieve a therapeutic benefit in affected patients.
窄谱中波紫外线(NB-UVB)疗法已成为治疗泛发性白癜风患者的首选治疗方法之一。联合应用局部药物的目的是提高 NB-UVB 诱导白癜风复色的疗效。
本研究旨在探讨联合应用局部他克莫司对 NB-UVB 治疗白癜风的复色作用。
本前瞻性单盲研究纳入了 80 例年龄在 12 岁以上的泛发性白癜风患者,他们的面部、躯干或四肢有对称分布的白癜风皮损。患者在身体左侧的对称皮损上每天应用 0.1%他克莫司软膏两次,右侧的对称皮损上不应用任何局部药物。患者还根据既定方案在非连续日每周接受全身 NB-UVB 照射三次。选择用于比较分析的皮损进行连续拍照,并由单盲观察者评估所获得的色素沉着程度或复色情况。根据 VASI 评分计算复色程度。记录初始复色开始的时间、获得的整体复色程度以及任何不良反应,并比较两侧选定皮损的结果。
在研究结束时,74 例患者(234 对对称白癜风皮损)可用于比较分析。左侧研究皮损的平均复色程度约为 71%(VASI 评分约为 4.0),而右侧对称分布皮损的复色程度约为 60.5%(VASI 评分约为 3.4)。此外,左侧研究皮损的复色开始时间早于右侧皮损。联合治疗未报告明显的不良反应。
联合应用局部他克莫司可增加 NB-UVB 治疗白癜风的整体复色程度,并减少受影响患者获得治疗益处所需的累积 NB-UVB 剂量。